Dr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES PARTNERS WITH CLAIRVO TO ADVANCE AI POWERED BRAIN HEALTH MANAGEMENT IN JAPAN

Cognetivity Neurosciences Ltd. has arranged a strategic partnership with Clairvo Technologies Inc., a wholly owned subsidiary of Marubeni Corp. (market cap $28-billion (U.S.)), aimed at revolutionizing brain health and addressing dementia-related challenges in Japan. Leveraging the power of artificial intelligence (AI), this partnership seeks to enhance preventative care and promote healthy aging within the Japanese population. As part of the collaboration, Clairvo, a leading company in medical AI diagnostic imaging products, will join forces with Cognetivity, renowned for its novel technology and testing platform CognICA. Together, the companies aim to integrate CognICA into Clairvo's existing AI portfolio of health and wellness products, providing innovative cognitive monitoring capabilities to the Japanese population.

Dementia and cognitive decline have become a global health care challenge, particularly in Japan where the aging population is on the rise. By harnessing the potential of AI and cognitive assessment technologies, Clairvo and Cognetivity aim to empower individuals and health care professionals in early detection and continuous monitoring of cognitive health. This pro-active approach will enhance the benefits of early intervention and personalized care, ultimately promoting brain health, well-being and improved quality of life. Earlier this year, the United States Food and Drug Administration (FDA) approved Lecanemab, a breakthrough drug to treat Alzheimer's, manufactured by Eisai Co. Ltd., a Japanese biopharmaceutical company, which requires early diagnosis to be effective.

Clairvo Technologies is a major player in the medical device industry and is committed to providing innovative solutions that enhance patient care and contribute to better health outcomes. Clairvo sources world-leading AI-driven medical technologies with strong validation to accelerate their adoption in Japan.

Dr. Sina Habibi, chief executive officer of Cognetivity Neurosciences, expressed his excitement about the collaboration, stating: "This is another significant development for Cognetivity in Japan, one of the largest and most advanced economies globally. However, Japan is facing a growing aging problem, with over 29 per cent of its population currently aged above 65. We are delighted to be working with our partners across the Japanese health care systems, from payers to providers and technology suppliers, to tackle this public health crisis and give the elderly population a brighter and healthier life. CognICA will enable wide-scale population screening and provide access to the incoming treatments at earlier stages, when they are most effective. Our AI platform enables clinicians to make more informed decisions when diagnosing, monitoring and treating patients at the provider level, and health care managers at population level. Japan can be a role model for the rest of the world and we are extremely excited by the opportunity."

Riichi Yamada, president and CEO of Clairvo Technologies, added: "We are thrilled to join forces with Cognetivity Neurosciences, a leader in cognitive assessment technology. This collaboration aligns perfectly with our commitment to introducing innovative AI solutions that improve health care outcomes. By incorporating Cognetivity's cutting-edge cognitive assessment platform into our offerings, we aim to provide health care professionals in Japan with a powerful tool to enhance cognitive health management and support early interventions."

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, United Kingdom, Europe and the Middle East, with regulatory approval in other regions expected in 2023.

We seek Safe Harbor.